On March 30, 2020, China’s National Medical Products Administration (NMPA) published two long-awaited implementing rules under the most recent Drug Administration Law (DAL): the Drug Registration Regulation (DRR) and the Drug Manufacturing Regulation (DMR). They are effective July 1, 2020. Below are highlights most relevant to multinational pharmaceutical companies with operations in China.
Sidley Austin LLP provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship. Readers should not act upon this information without seeking advice from professional advisers.
Attorney Advertising—Sidley Austin LLP, One South Dearborn, Chicago, IL 60603. +1 312 853 7000. Sidley and Sidley Austin refer to Sidley Austin LLP and affiliated partnerships, as explained at www.sidley.com/disclaimer.
© Sidley Austin LLP